NEW YORK, Feb. 3, 2015 /PRNewswire-USNewswire/ -- Elysium Health LLC, a provider of a new category of scientifically validated dietary supplements, today announced the release of BASISTM, an advanced daily supplement designed to target metabolic repair and optimization. BASISTM is the first of the company's upcoming line of dietary supplements created to support metabolic and cellular health, enhance biological functions such as muscle repair and inflammatory response, and promote healthy aging with memory and cardiovascular health. With the release of BASISTM, Elysium Health sets the stage for the expansion in 2015 of its dietary supplements pipeline.
Created in 2014 to develop a new category of supplements based on sound scientific research, Elysium Health researches, develops, licenses and markets supplements that target biological deficiencies through new pathways that complement diet and exercise. Elysium Health has brought together some of the world's leading scientists and healthcare experts to help guide the discovery and validation of these new supplements.
"Recent technological innovations, combined with advancements in our understanding of basic biological mechanisms, finally give us this opportunity to develop novel products that may provide a meaningful impact on individuals' health," said Dr. Leonard Guarente, co-founder and chief scientist of Elysium Health who has led research efforts at the Massachusetts Institute of Technology (MIT) for 34 years and serves as the director of the Glenn Laboratory for the Science of Aging. "We are thrilled to introduce BASISTM and excited about Elysium's potential to build upon the scientific understanding of how natural compounds can enhance an array of key biological functions, and then translate that knowledge into products that may help people improve and sustain their health."
Elysium Health has established management and scientific teams that are unprecedented in the dietary supplements industry. Guarente and his two co-founders combine decades of important scientific discovery with experience in areas such as mobile applications and healthcare technologies.
In addition to his work at MIT, Guarente is a pioneer in the study of the genetic and molecular foundations of aging. His work on the links between diet and physiology includes the identification of a group of enzymes known as sirtuins as key regulators of lifespan.
Eric Marcotulli, co-founder and chief executive officer, is a former partner at Silicon Valley-based Sequoia Capital, where he led the firm's growth efforts in mobile technologies, with a focus on consumer-facing advancements. In addition to working with leading healthcare startups, Marcotulli partnered with healthcare entrepreneurs innovating in new commerce platforms.
Dan Alminana, co-founder and chief operating officer, previously was a vice president at JP Morgan Securities, where he led its Silicon Valley venture unit. In this role, Alminana worked closely with the international healthcare community, including leading investors and the most advanced, forward-thinking startups in the U.S., Asia, and Europe.
To support Elysium Health's business structure and mission, Guarente, Marcotulli and Alminana have structured a scientific advisory board composed of more than 30 of the world's leading industry innovators, scientific researchers and clinicians, including five Nobel laureates. This renowned scientific team, whose members are responsible for many important discoveries and advancements in areas ranging from DNA sequencing to cancer, neuroscience, immunology and aging, is working with Elysium Health's founders to contribute its collective knowledge, evaluate data and support a high level of scientific rigor and transparency in the development of Elysium Health's products. The team's involvement is intended to advance the overall development of effective, safe and scientifically sound dietary supplements. Elysium Health's open platform approach will enable its scientific advisory board, as well as other scientific contributors, to collaborate on new discoveries, accelerating the exchange of ideas and research findings.
The Elysium Health model also includes participation from an array of health industry advisors with a strong commitment to health care innovation and expertise in areas such as regulatory, customer insights and health technologies.
Elysium's scientific advisory board includes:
- Aaron Ciechanover, distinguished research professor at Technion; recipient of the 2004 Nobel Prize in Chemistry
- Daniel Fabricant, former director, division of dietary supplements for the U.S. Food and Drug Administration and currently CEO, Natural Products Association
- Eric Kandel, M.D., professor of biochemistry and biophysics at Columbia University and Kavli Professor of Brain Science, recipient of the 2000 Nobel Prize in Physiology or Medicine
- Martin Karplus, Theodore William Richards Professor of Chemistry at Harvard, Emeritus; recipient of the 2013 Nobel Prize in Chemistry
- Tom Sudhof, professor of molecular and cellular physiology at Stanford School of Medicine; recipient of the 2013 Nobel Prize in Physiology or Medicine
- Jack Szostak, professor of Genetics at Harvard Medical School, Alex A. Rich Distinguished Investigator, Department of Molecular Biology at MGH; recipient of the 2009 Nobel Prize in Physiology or Medicine
"Our scientific team is dedicated to the idea of making scientific discovery and advancement accessible, understandable and directly applicable to an individual's health," Marcotulli said. "This philosophy forms the core of Elysium Health, a platform that offers consumers an entirely new way to think about managing their health and also provides the world's best researchers a way to bring scientific innovation directly to the public."
A daily product for metabolic health, BASISTM contains two novel compounds. The first, nicotinamide riboside, is a precursor of the critical coenzyme NAD+, which is involved in metabolic processes such as energy production, DNA repair, cellular detoxification, the inflammatory response, and protein folding. The second component of BASISTM is a new polyphenol compound pterostilbene, which, like the NAD+ precursor, promotes metabolic health. Both compounds have been validated in numerous laboratories and been shown to improve metabolic health in scientific studies. BASISTM is the first of several Elysium Health products scheduled for release over the next 12 to 18 months that will target areas such as muscle health, metabolism, brain and cardiovascular function and gut health. BASISTM is available to consumers exclusively through Elysium Health's Web site (www.ElysiumHealth.com) for $60.00 for a 30-day supply or for $50.00 per month with an Elysium Health subscription.
"Outstanding customer experience and product quality are fundamental to Elysium Health's mission," Alminana said. "Our commitment to these ideals drives every aspect of our decision-making, from the sourcing of materials to manufacturing processes to our interactions with Elysium Health customers. Our intent is to create a new model in this industry that establishes a true dialogue and partnership with customers in support of lifelong health, and we look forward to bringing additional products to market."
About Elysium Health LLC
Working directly with the world's leading scientists and clinicians, Elysium Health translates advances in science, research and technology into effective, scientifically sound dietary supplements that target biological deficiencies through new pathways that complement diet and exercise. Elysium Health makes its products available exclusively through its online platform, www.elysiumhealth.com. Visit Elysium Health at:
SOURCE Elysium Health